Overview

Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease

Status:
Terminated
Trial end date:
2020-03-11
Target enrollment:
0
Participant gender:
All
Summary
This is a multicenter, phase 2 study to evaluate the safety, tolerability, pharmacodynamics (PD), efficacy, and pharmacokinetics (PK) of ACE-083 in patients with Charcot-Marie-Tooth Disease Type 1 and Type X (CMT1 and CMTX), to be conducted in two parts. Part 1 is non-randomized, open-label, dose-escalation and Part 2 is randomized, double-blind, and placebo-controlled.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Acceleron Pharma Inc.
Acceleron Pharma, Inc.
Criteria
Key Inclusion Criteria

1. Age ≥ 18 years

2. Diagnosis of CMT1 or CMTX confirmed by:

1. Clinical presentation and electrodiagnostics

2. Genetically-confirmed CMT1 or CMTX for the patient or first-degree relative

3. Part 1:

1. Six-minute walk distance (6MWD) of at least 150 meters (without a brace or
walker)

2. Independent ambulation for at least 10 meters, without a brace

3. Left and right ankle plantar flexion MRC grade 4+ to 5, inclusive

Part 2:

1. 6MWD ≥ 150 and ≤ 500 meters (without a brace or walker); a maximum of 20% of
enrolled patients with 6MWD ≥ 450 meters will be included

2. Left and right ankle plantar flexion MRC grade 4- to 5, inclusive

4. Left and right ankle dorsiflexion Medical Research Council (MRC) manual muscle testing
(MMT) grade 3 to 4+ inclusive. No more than 12 of the 40 subjects may have a grade of
3 or 3+ on one or both sides.

5. Females of childbearing potential must have negative urine pregnancy test prior to
enrollment and use highly effective birth control methods during study participation
and for 8 weeks following the last dose of ACE-083. Males must agree to use a condom
during any sexual contact with females of childbearing potential while participating
in the study and for 8 weeks following the last dose of ACE-083, even if he has
undergone a successful vasectomy.

6. Ability to adhere to the study visit schedule/procedures, and to understand and comply
with protocol requirements

7. Signed written informed consent

Key Exclusion Criteria

1. History of active malignancy, with the exception of fully excised or treated basal
cell carcinoma, cervical carcinoma in-situ, or ≤ 2 squamous cell carcinomas of the
skin

2. Symptomatic cardiopulmonary disease, significant functional impairment, significant
orthopedic or neuropathic pain, or other co morbidities that in the opinion of the
investigator would limit a patient's ability to complete strength and/or functional
assessments on study

3. Type 1 or type 2 diabetes mellitus

4. Thyroid disorder unless condition is stable with no change in treatment for at least 4
weeks before the first dose and no expected change for duration of study

5. Renal impairment (serum creatinine ≥ 2 times the upper limit of normal (ULN])

6. Aspartate transaminase (AST) and/or alanine transaminase (ALT) ≥ 3 times ULN

7. Increased risk of bleeding (i.e., due to hemophilia, platelet disorders, or use of any
anticoagulation/platelet modifying therapies up to 2 weeks prior to Study Day 1 and
for duration of study; low dose aspirin [≤ 100 mg daily] is permitted)

8. Severe deformity or ankle fixation that would sufficiently limit passive range of
motion to affect assessment of dorsiflexion strength

9. Major surgery within 4 weeks prior to Study Day 1

10. Chronic pharmacologic doses of systemic corticosteroids (≥ 2 weeks) within 4 weeks
before Study Day 1 and for duration of study;
intra-articular/topical/inhaled/intranasal physiologic doses of systemic
corticosteroids are permitted

11. Androgens, growth hormone, insulin or oral hormone replacement therapy within 6 months
before Study Day 1 and for duration of study; topical physiologic androgen replacement
is permitted

12. Any change in medications potentially affecting muscle strength or function within 4
weeks of Study Day 1 and for duration of study (e.g., creatinine, CoQ10, systemic
beta-adrenergic agonists)

13. Previous exposure to any investigational agent potentially affecting muscle volume,
muscle strength, or muscle or nerve function within 5 half-lives of last dose plus an
additional 8-week washout period (or 12 weeks prior to Study Day 1 if half-life is
unknown)

14. Any previous or current exposure to ACE-083

15. Significant change in physical activity or exercise (e.g., significant increase or
decrease in intensity or frequency) within 8 weeks before Study Day 1 or inability to
maintain the baseline level of physical activity throughout the study

16. Any condition that would prevent MRI scanning or compromise the ability to obtain a
clear and interpretable scan of the lower leg, as applicable (e.g., knee/hip
replacement metallic implants)

17. Known active substance abuse, including alcohol

18. History of sensitivity to protein pharmaceuticals

19. Female that is lactating/breast-feeding